{"id":41159,"date":"2023-10-31T10:44:59","date_gmt":"2023-10-31T08:44:59","guid":{"rendered":"https:\/\/www.ipsen.com\/?p=41159"},"modified":"2023-11-30T07:54:42","modified_gmt":"2023-11-30T05:54:42","slug":"innovating-for-people-living-with-primary-biliary-cholangitis","status":"publish","type":"post","link":"https:\/\/www.ipsen.com\/rare-diseases\/innovating-for-people-living-with-primary-biliary-cholangitis\/","title":{"rendered":"Innovating for people living with primary biliary cholangitis"},"content":{"rendered":"\n
\n
\n

At Ipsen we have been focused on developing new and innovative treatments for rare diseases for many years in endocrinology, rare bone disease and more recently in rare liver disease. This focus continues to be a core part of our growth strategy.<\/p>\n\n\n\n

Here, Sandra Silvestri, Chief Medical Officer at Ipsen<\/strong><\/a>, shares her thoughts on the challenges and benefits of innovating for the rare, autoimmune, cholestatic liver disease, primary biliary cholangitis or PBC.<\/p>\n\n\n

\n
\n \n
\n

<\/h2>\n

<\/p>\n <\/div>\n\n \n

\n